Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347016 · ClinicalTrials.gov registry record · Phase 3

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
311
Enrollment target
20
Study locations

NCT06347016 is a Phase 3 study of Severe Hypertriglyceridemia that is active but no longer recruiting, run by Arrowhead Pharmaceuticals. The registered enrollment target is 311 participants, below the 386-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347016, a Phase 3 study of Severe Hypertriglyceridemia, is active but no longer recruiting, sponsored by Arrowhead Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
311 participants
Enrollment target
20
Study locations

Study Summary

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Conditions Studied

Severe Hypertriglyceridemia

Interventions

  • DRUG Placebo
  • DRUG Plozasiran Injection

Study Locations (20)

California

  • Research Site 3 - Beverly Hills
  • Research Site 4 - Canoga Park
  • Research Site 5 - Huntington Beach
  • Research Site 6 - Lincoln
  • Research Site 7 - Long Beach
  • Research Site 8 - Oxnard

Florida

  • Research Site 9 - Clearwater
  • Research Site 10 - North Miami
  • Research Site 11 - Sarasota

Indiana

  • Research Site 14 - Elkhart
  • Research Site 15 - Indianapolis
  • Research Site 16 - South Bend

Alabama

  • Research Site 1 - Birmingham
  • Research Site 2 - Mobile

Georgia

  • Research Site 12 - Lawrenceville
  • Research Site 13 - Sugar Hill

Kansas

  • Research Site 17 - Overland Park
  • Research Site 18 - Topeka

Louisiana

  • Research Site 19 - Metairie

Maryland

  • Research Site 20 - Annapolis

Trial Details

FieldValue
Enrollment Target 311 participants
Start Date 2024-07-23
Est. Completion 2026-09
Phase Phase 3

Sponsor

Arrowhead Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06347016

The ClinicalTrials.gov registry entry for NCT06347016 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 386-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (19% lower). The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06347016 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT06347016 about?

NCT06347016 is a clinical study titled "Study of Plozasiran in Adults With Severe Hypertriglyceridemia". This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and...

What is the current status of trial NCT06347016?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2024-07-23. Estimated completion is 2026-09.

What conditions does trial NCT06347016 study?

This clinical trial studies the following conditions: Severe Hypertriglyceridemia.

What interventions are being tested in trial NCT06347016?

The interventions under investigation include: Placebo (DRUG), Plozasiran Injection (DRUG).

Who is sponsoring clinical trial NCT06347016?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347016 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Severe Hypertriglyceridemia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.